Oncotarget cover image

Oncotarget

Press Release: Imaging With Polypeptide Fusion Protein Targets Bladder Cancer

Sep 8, 2022
Discover the development of a targeted imaging probe for detecting bladder cancer using polypeptide fusion proteins. Learn about the high sensitivity and selectivity of a NIR probe in labeling tumor tissue, showcasing potential for clinical translation and patient imaging.
04:44

Podcast summary created with Snipd AI

Quick takeaways

  • Development of a polypeptide-based NIR imaging agent for detecting cells with overexpressed epidermal growth factor receptors in urothelial carcinoma.
  • Potential future applications in imaging canine tumors during systoscopy and broader implications in oncology research.

Deep dives

Development of a New NIR Imaging Agent for Urothelial Carcinoma Detection

Researchers from Purdue University and Indiana University collaborated to create a polypeptide-based NIR imaging agent designed to detect cells with overexpressed epidermal growth factor receptors, common in 80% of urothelial carcinoma cases. The agent, consisting of an Alastin-like polypeptide fused with epidermal growth factor and conjugated with CY 5.5, exhibited high specificity and sensitivity. Testing in canine and human cells and tissues, the probe showed minimal signal from normal tissues and significant fluorescence in tumor tissues, indicating enhanced selectivity for bladder cancer.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner